A renewed push into early bladder cancer
Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.
Clinical and corporate developments over the Christmas period
A decent showing for Pfizer/Roche in haemophilia sets up a rivalry with Uniqure/CSL, and a smattering of deals get done before the year end – and before JP Morgan.
When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
Bispecifics move beyond cancer
Hitting two targets with one molecule is all the rage in oncology, but Roche and others have taken this work into other disease areas.
Looking beyond Roche’s Tigit bombshell
The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?
Up-front licensing costs hit a five-year high
But the pace of biopharma asset deals dips. Are the two trends related?